These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 9162213)

  • 1. Seasonal effects in prolactin response to m-chlorophenylpiperazine challenge in obsessive-compulsive disorder.
    Grossman R; Cohen L; Rosen J; DeCaria C; Hollander E
    Biol Psychiatry; 1996 Jun; 39(11):982-5. PubMed ID: 9162213
    [No Abstract]   [Full Text] [Related]  

  • 2. Allelic variants of the serotonin(2C) receptor and neuroendocrinological responses to the serotonin(2C) receptor agonist m-chlorophenylpiperazine in healthy male volunteers.
    Kühn KU; Quednow BB; Bagli M; Meyer K; Feuchtl A; Westheide J; Frahnert C; Maier W; Rao ML
    Pharmacopsychiatry; 2002 Nov; 35(6):226-30. PubMed ID: 12518270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Headache response to m-chlorophenylpiperazine in obsessive-compulsive disorder and normal controls.
    Wong CM; Hollander E
    Biol Psychiatry; 1996 Sep; 40(6):544-6. PubMed ID: 8879476
    [No Abstract]   [Full Text] [Related]  

  • 4. Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa.
    Hadigan CM; Walsh BT; Buttinger C; Hollander E
    Biol Psychiatry; 1995 Apr; 37(8):504-11. PubMed ID: 7619973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures.
    Stein DJ; Hollander E; DeCaria CM; Simeon D; Cohen L; Aronowitz B
    Biol Psychiatry; 1996 Sep; 40(6):508-13. PubMed ID: 8879471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
    Gross-Isseroff R; Cohen R; Sasson Y; Voet H; Zohar J
    Neuropsychobiology; 2004; 50(3):200-5. PubMed ID: 15365215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower levels of whole blood serotonin in obsessive-compulsive disorder and in schizophrenia with obsessive-compulsive symptoms.
    Ma N; Tan LW; Wang Q; Li ZX; Li LJ
    Psychiatry Res; 2007 Feb; 150(1):61-9. PubMed ID: 17291595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
    Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR
    Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
    de Leeuw AS; Westenberg HG
    J Psychiatr Res; 2008 Sep; 42(11):894-901. PubMed ID: 18533183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval.
    Nappi RE; Sances G; Brundu B; De Taddei S; Sommacal A; Ghiotto N; Polatti F; Nappi G
    Hum Reprod; 2005 Dec; 20(12):3423-8. PubMed ID: 16123089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
    Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
    Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
    Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
    Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence.
    Patkar AA; Mannelli P; Hill KP; Peindl K; Pae CU; Lee TH
    Hum Psychopharmacol; 2006 Aug; 21(6):367-75. PubMed ID: 16915581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
    Hollander E; DeCaria CM; Nitescu A; Gully R; Suckow RF; Cooper TB; Gorman JM; Klein DF; Liebowitz MR
    Arch Gen Psychiatry; 1992 Jan; 49(1):21-8. PubMed ID: 1728249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
    Zohar J; Mueller EA; Insel TR; Zohar-Kadouch RC; Murphy DL
    Arch Gen Psychiatry; 1987 Nov; 44(11):946-51. PubMed ID: 3675134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder.
    Hollander E; Stein DJ; DeCaria CM; Saoud JB; Klein DF; Liebowitz MR
    Biol Psychiatry; 1993 May; 33(10):747-9. PubMed ID: 8353170
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.
    Eriksson T
    Int Clin Psychopharmacol; 2007 Jan; 22(1):57-61. PubMed ID: 17159461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of magical thinking in obsessive compulsive disorder.
    Einstein DA; Menzies RG
    Behav Res Ther; 2004 May; 42(5):539-49. PubMed ID: 15033500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose paroxetine treatment for an adolescent with obsessive-compulsive disorder comorbid with Asperger's disorder.
    Sasayama D; Sugiyama N; Imai J; Hayashida A; Harada Y; Amano N
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):251. PubMed ID: 19335398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.